Astria Therapeutics/$ATXS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Astria Therapeutics
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Ticker
$ATXS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
78
Website
ATXS Metrics
BasicAdvanced
$375M
-
-$1.88
0.45
-
Price and volume
Market cap
$375M
Beta
0.45
52-week high
$12.70
52-week low
$3.56
Average daily volume
301K
Financial strength
Current ratio
17.386
Quick ratio
16.932
Long term debt to equity
1.269
Total debt to equity
1.75
Profitability
Management effectiveness
Return on assets (TTM)
-22.56%
Return on equity (TTM)
-32.89%
Valuation
Price to book
1.93
Price to tangible book (TTM)
1.93
Price to free cash flow (TTM)
-3.97
Free cash flow yield (TTM)
-25.19%
Free cash flow per share (TTM)
-167.50%
Growth
Earnings per share change (TTM)
-16.79%
3-year earnings per share growth (CAGR)
-31.13%
What the Analysts think about ATXS
Analyst ratings (Buy, Hold, Sell) for Astria Therapeutics stock.
Bulls say / Bears say
Cantor Fitzgerald initiated coverage of Astria Therapeutics with an 'Overweight' recommendation and a price target suggesting a 428.96% upside, indicating strong confidence in the company's growth potential. (nasdaq.com)
The company's lead candidate, STAR-0215, demonstrated a 90-95% reduction in monthly attack rates for hereditary angioedema in Phase 1b/2 trials, showcasing its potential efficacy. (stocktitan.net)
Astria Therapeutics completed a $125 million underwritten offering in January 2024, bolstering its financial position to support ongoing and future clinical developments. (stocktitan.net)
The company reported a net loss of $17.7 million for Q3 2023, reflecting increased research and development expenses and raising concerns about profitability. (gurufocus.com)
Despite positive analyst ratings, the stock's current price of $6.37 is significantly below the average one-year price target of $27.03, suggesting potential market skepticism. (nasdaq.com)
The projected annual revenue for Astria Therapeutics is $0 million, indicating a lack of current product revenue and reliance on future approvals and market acceptance. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 13 Jul 2025.
ATXS Financial Performance
Revenues and expenses
ATXS Earnings Performance
Company profitability
ATXS News
AllArticlesVideos
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·4 weeks ago
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit
Business Wire·1 month ago
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Astria Therapeutics stock?
Astria Therapeutics (ATXS) has a market cap of $375M as of July 28, 2025.
What is the P/E ratio for Astria Therapeutics stock?
The price to earnings (P/E) ratio for Astria Therapeutics (ATXS) stock is 0 as of July 28, 2025.
Does Astria Therapeutics stock pay dividends?
No, Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Astria Therapeutics dividend payment date?
Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders.
What is the beta indicator for Astria Therapeutics?
Astria Therapeutics (ATXS) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.